The incidence and prevalence of End-Stage Renal Disease (ESRD) secondary to Diabetic Nephropathy (DN) have been progressively increasing, reaching pandemic proportions over the past 20 years. Diabetes mellitus is responsible for more than 40% of all cases of ESRD in the United States. Despite that, the treatment of DN is still suboptimal. Both the elderly and diabetic populations are among the fastest growing categories. While several guidelines are available for management of DN in the general population, elderly patients have unique characteristics that may require adaptation of the general therapeutic guidelines used for the general population. Current therapy directed at delaying the progression of DN in elderly includes optimal glycemic and blood pressure control, proteinuria/albuminuria reduction, interruption of the renin-angiotensin-aldosterone system through the use of angiotensin converting enzyme inhibitors and angiotensin type-1 receptor blockers, along with dietary modification and cholesterol lowering agents. This review highlights the available standard therapeutic approaches to manage progressive DN in elderly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760431 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Gender-related diabetic nephropathy: Yes or no.
J Res Med Sci
November 2024
Water and Electrolytes Research Center, and Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran.
Chlorogenic acid inhibits NLRP3 inflammasome activation through Nrf2 activation in diabetic nephropathy.
PLoS One
January 2025
Department of Nephrology, Pu'er People's Hospital, Pu'er, Yunnan, China.
Diabetic nephropathy (DN) is the single largest cause of end-stage renal disease (ESRD). Inflammation reaction mediated by NLRP3 inflammasome and Nrf2-related oxidative stress have been considered to play a very important role in the progress of diabetic nephropathy (DN). Effective drugs for the treatment of diabetic nephropathy still need to be explored.
View Article and Find Full Text PDFNeutrophil-Lymphocyte Ratio and Urine Albumin-Creatinine Ratio As Indicators of Microvascular Complications in Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Cureus
December 2024
Internal Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, IND.
Background Type 2 diabetes mellitus (T2DM) is associated with a high risk of developing microvascular complications such as diabetic nephropathy, diabetic neuropathy (DN), and diabetic retinopathy (DR), leading to significant morbidity. Early detection of these complications is crucial for improving patient outcomes. Neutrophil-lymphocyte ratio (NLR) and urine albumin-creatinine ratio (UACR) show promise as cost-effective and accessible biomarkers for the early detection of microvascular complications in T2DM.
View Article and Find Full Text PDFLong noncoding RNA Gm4419 promotes mesangial cell proliferation and extracellular matrix accumulation the miR-455-3p/histone deacetylase 2 axis.
Heliyon
January 2025
Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Long noncoding RNAs may function as competitive endogenous RNAs by sponging microRNAs, thereby contributing to the progression of diabetic nephropathy. In this study, a potential diabetic nephropathy-related long noncoding-microRNA-mRNA axis, Gm4419-miR-455-3p-, was predicted using bioinformatics methods. To verify the role of the Gm4419-miR-455-3p- axis in diabetic nephropathy, an high glucose-induced mesangial cell model was established.
View Article and Find Full Text PDFA comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis.
Front Endocrinol (Lausanne)
January 2025
Department of Nephrology, Affiliated Bao'an Hospital of Shenzhen, The Second School of Clinical Medicine, Southern Medical University, Shenzhen, China.
Objectives: The study will evaluate the effectiveness and safety of finerenone in patients diagnosed with diabetic kidney disease (DKD).
Methods: Various databases including PubMed, Sinomed, Web of Science, Embase, Clinical Trials, and Cochrane Library were systematically reviewed for pertinent studies published from the beginning to February 2024.This meta-analysis utilized RevMan 5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!